- Home
- ERNA vs CMMB Comparison
ERNA vs CMMB Comparison
Compare ERNA & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ERNA | CMMB |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | United States | Israel |
| Employees | N/A | 16 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 10.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ERNA | CMMB |
|---|---|---|
| Price | $1.19 | $1.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $26.50 |
| AVG Volume (30 Days) | ★ 187.7K | 84.0K |
| Earning Date | 11-07-2025 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.08 | $1.60 |
| 52 Week High | $11.07 | $8.80 |
Technical Indicators
Market Signals| Indicator | ERNA | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 45.72 | 33.76 |
| Support Level | $1.15 | $1.70 |
| Resistance Level | $1.29 | $1.85 |
| Average True Range (ATR) | 0.12 | 0.15 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 40.63 | 22.50 |
Price Performance
Historical ComparisonAbout ERNA Eterna Therapeutics Inc.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.